Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Eton Pharmaceuticals (ETON) Interest & Investment Income (2019 - 2025)

Eton Pharmaceuticals' Interest & Investment Income history spans 4 years, with the latest figure at -$592000.0 for Q3 2025.

  • For Q3 2025, Interest & Investment Income fell 7300.0% year-over-year to -$592000.0; the TTM value through Sep 2025 reached -$2.7 million, down 2519.61%, while the annual FY2018 figure was $164000.0, N/A changed from the prior year.
  • Interest & Investment Income for Q3 2025 was -$592000.0 at Eton Pharmaceuticals, up from -$1.0 million in the prior quarter.
  • Across five years, Interest & Investment Income topped out at -$8000.0 in Q3 2024 and bottomed at -$1.0 million in Q2 2025.
  • The 3-year median for Interest & Investment Income is -$124000.0 (2023), against an average of -$335111.1.
  • The largest annual shift saw Interest & Investment Income soared 91.27% in 2024 before it crashed 9245.45% in 2025.
  • A 3-year view of Interest & Investment Income shows it stood at -$31000.0 in 2023, then soared by 74.19% to -$8000.0 in 2024, then tumbled by 7300.0% to -$592000.0 in 2025.
  • Per Business Quant, the three most recent readings for ETON's Interest & Investment Income are -$592000.0 (Q3 2025), -$1.0 million (Q2 2025), and -$1.0 million (Q1 2025).